secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001178913-25-002341
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIL204 shows dose-dependent inhibition in KRAS G12D lung cancer cells in preclinical study
--------------------------------------------------------------------------------

- Preclinical study demonstrates significant dose-dependent inhibition of human lung cancer cells with KRAS G12D mutation.
- Company plans to release results of new study on previously untested KRAS mutation shortly; if positive, could support pan-KRAS potential.
- SIL204's lipid-conjugated delivery system validated; overcoming a key barrier for siRNA in solid tumors.
- Company continues to prepare for Phase 2/3 trial initiation in Q2 2026 for KRAS-driven solid tumors.
- Builds on prior efficacy in pancreatic and colorectal cancer models; KRAS mutations occur in ~30% of lung cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/0001178913-25-002341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002341/zk2533417.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer